A team of scientists at UCL have found that blood tests measuring the hallmark Alzheimer’s protein, beta-amyloid (amyloid), could radically reduce the cost of clinical trials and potentially open the door to treating the disease earlier.
Suddenly, phospho-tau217 looks to be the most robust plasma biomarker for Alzheimer’s disease yet. That’s the general—and enthusiastic—consensus from two papers and several presentations at this year’s virtual Alzheimer’s Association International Conference, being held July 27 to 31.
As it happens, to find out what is going on in the brain of someone with Alzheimer’s disease, all it takes is a drop of blood. Catch-up in this article from the Alz Forum
Multi-instrumentalist and Postdoctoral research fellow at University College London looking for fluid biomarkers of synaptic dysfunction in genetic FTD.
Post-doctoral clinical research associate and Neurology Registrar at UCL and National Hospital for Neurology and Neurosurgery researching Biofluid biomarkers of Alzheimer’s disease, rediscovering Odissi.
Almost Tennis superstar, MD-PhD Student at the Federal University of Rio Grande do Sul, Brazil. In his third year of Medicine, which in Brazil can be combined with a PhD understanding vascular risk factors contribution for the etiology and progression of Alzheimer’s disease using neuroimaging and fluid biomarkers.
Researching Fluid biomarkers as Professor of Neurochemistry, Senior Consultant in Clinical Chemistry at the University of Gothenburg, Sweden, and University College London. Representing the Alzheimer’s Association ISTAART Fluid biomarkers for neurodegenerative dementias PIA.
Adam Smith
Alz Forum
Dementia Researcher